Literature DB >> 12805061

Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.

Genovefa A Papanicolaou1, Jean-Baptiste Latouche, Cuiwen Tan, Jakob Dupont, Jeffrey Stiles, Eric G Pamer, Michel Sadelain.   

Abstract

Cytomegalovirus (CMV) is a major threat in patients undergoing allogeneic bone marrow transplantation. The adoptive transfer of CMV-specific cytotoxic T lymphocytes (CTLs) expanded from the blood of CMV-seropositive donors has been shown to effectively control CMV infection. However, the requirement for safe and effective antigen-presenting cells (APCs) for each patient precludes broad applicability of this successful form of therapy. Here we analyze the ability of artificial APCs (AAPCs) to activate and expand CMV-specific CTLs from peripheral blood of seropositive HLA A2.1+ donors. We demonstrate that AAPCs expressing the CMV P495 peptide or the full-length pp65 protein stimulate P495-specific CTLs at least as effectively as autologous, peptide-pulsed, peripheral blood mononuclear cells or EBV-transformed B cells. Starting from 100 mL of blood, the AAPCs reliably yield clinically relevant CTL numbers after a single stimulation. CTLs activated on AAPCs effectively kill CMV-infected fibroblasts and have a Tc1 memory effector phenotype identical to that of CTLs generated with autologous APCs. AAPCs thus offer a rapid, controlled, convenient, and highly reproducible system for expanding CMV-specific CTLs. Furthermore, the CTL expansion obtained with AAPCs encoding full-length pp65 indicates that AAPCs may be used to present known as well as unknown CTL epitopes in the context of the AAPC's HLA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805061     DOI: 10.1182/blood-2003-02-0345

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Authors:  Lawrence G Lum; Mayur Ramesh; Archana Thakur; Subhashis Mitra; Abhinav Deol; Joseph P Uberti; Philip E Pellett
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-05       Impact factor: 5.742

2.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

3.  Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.

Authors:  Sonja Obermann; Susanne Petrykowska; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

4.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

5.  Measurement of cytotoxic T lymphocyte activity of human cytomegalovirus seropositive individuals by a highly sensitive coupled luminescent method.

Authors:  Henry Ogbomo; Janina Geiler; Anke Leutz; Kristina von Kietzell; Martin Michaelis; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-10-08       Impact factor: 3.402

Review 6.  New cell sources for T cell engineering and adoptive immunotherapy.

Authors:  Maria Themeli; Isabelle Rivière; Michel Sadelain
Journal:  Cell Stem Cell       Date:  2015-04-02       Impact factor: 24.633

7.  Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.

Authors:  Anthony Garnier; Mohamad Hamieh; Aurélie Drouet; Jérôme Leprince; Denis Vivien; Thierry Frébourg; Brigitte Le Mauff; Jean-Baptiste Latouche; Olivier Toutirais
Journal:  Immunol Cell Biol       Date:  2016-02-29       Impact factor: 5.126

Review 8.  Novel strategies for adoptive therapy following HLA disparate transplants.

Authors:  Richard J O'Reilly; Aisha Hasan; Ekaterina Doubrovina; Guenther Koehne; Susan Prockop
Journal:  Best Pract Res Clin Haematol       Date:  2011-09       Impact factor: 3.020

Review 9.  Use of humanized severe combined immunodeficient mice for human vaccine development.

Authors:  Gloria C Koo; Aisha Hasan; Richard J O'Reilly
Journal:  Expert Rev Vaccines       Date:  2009-01       Impact factor: 5.217

10.  Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants.

Authors:  Richard J O'Reilly; Ekaterina Doubrovina; Deepa Trivedi; Aisha Hasan; Wouter Kollen; Guenther Koehne
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.